Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

¼ö¼ú ÈÄ ±¹¼ÒÀç¹ßµÈ Á÷¾Ó¾ÏÀÇ ¹æ»ç¼±Ä¡·á °á°ú Radiotherapy of Locally Recurrent Rectal Carcinoma

´ëÇѹæ»ç¼±Á¾¾çÇÐȸÁö 1999³â 17±Ç 1È£ p.36 ~ 41
¼Ò¼Ó »ó¼¼Á¤º¸
Á¤ÇöÁÖ/Hyeon Ju Jeong ½Å¿µÁÖ/¾ç±¤¸ð/¼­Çö¼÷/ÀüÇÏÁ¤/À̸íÀÚ/Young Ju Shin/Kwang Mo Yang/Hyun Suk Suh/Hachung Chun/Myung Za Lee

Abstract

¼­ ·Ð : ¿ÏÄ¡ ¸ñÀûÀÇ ÀýÁ¦¼úÀ» ½ÃÇà ÈÄ ±¹¼ÒÀç¹ßµÈ Á÷Àå¾ÏȯÀÚ¿¡ ´ëÇÑ ¹æ»ç¼±Ä¡·á °á°ú
¹× »ýÁ¸À²¿¡ ¹ÌÄ¡´Â ¿¹ÈÄÀÎÀÚ¿¡ ´ëÇØ Æò°¡ÇÏ°íÀÚ ÇÏ¿´´Ù.
´ë»ó ¹× ¹æ¹ý : 1982³â 7¿ùºÎÅÍ 1996³â 5¿ù±îÁö ÀÎÁ¦´ëºÎ¼Ó ¹éº´¿ø°ú ÇѾç´ëºÎ¼Óº´¿ø ¹æ
»ç¼±Á¾¾çÇаú¿¡¼­ ±¹¼ÒÀç¹ßµÈ Á÷Àå¾ÏÀ¸·Î ¹æ»ç¼±Ä¡·á¸¦ ½ÃÇà¹ÞÀº ÃÑ 28¸íÀÇ È¯ÀÚ¸¦ ´ë»óÀ¸
·Î Ä¡·á°á°ú¿¡ ´ëÇÑ ÈÄÇâÀû ºÐ¼®À» ½ÃÇàÇÏ¿´´Ù. ³²³àºñ´Â 14:14À̾ú°í, ¿¬·ÉºÐÆ÷´Â 31¼¼¿¡¼­
72¼¼ »çÀÌ·Î ³ªÅ¸³µ´Ù(Æò±Õ ¿¬·É:54.5¼¼). ÀÏÂ÷ ¼ö¼ú ÈÄ ±¹¼Ò Àç¹ß±îÁöÀÇ ±â°£Àº 4°³¿ù¿¡¼­
46°³¿ù·Î °üÂûµÇ¾ú´Ù(Áß¾Ó°ª:10°³¿ù). ¹æ»ç¼±Ä¡·á´Â ÃÑ 27§í¿¡¼­ 64.8§í(median; 51.2§í)°¡
Á¶»çµÇ¾ú´Ù. 50.0§í ÀÌÇÏ·Î Á¶»çµÈ ȯÀÚ´Â ¸ðµÎ 11·Ê·Î ³ªÅ¸³µÀ¸¸ç, 17·Ê¿¡¼­ 50.0§í ÀÌ»óÀÌ
Á¶»çµÇ¾ú´Ù.
°á °ú : Áõ»ó¿ÏÈ­´Â Àüü ȯÀÚ Áß 17·Ê(60.7%)¿¡¼­ °üÂûµÇ¾ú°í, ÃâÇ÷ ¹× ÅëÁõÀ» È£¼ÒÇÑ È¯
ÀÚÀÇ °æ¿ì °¢±â 100%¿Í 40%¿¡¼­ Áõ»ó¿ÏÈ­°¡ °üÂûµÇ¾ú´Ù. Áõ»ó¿ÏÈ­Á¤µµÀÇ ¹æ»ç¼± Á¶»ç·®¿¡
µû¸¥ Â÷ÀÌ´Â °üÂûµÇÁö ¾Ê¾Ò´Ù. ¹æ»ç¼±Ä¡·á ½ÃÀÛÀϺÎÅÍ Àüü ȯÀÚÀÇ Áß¾Ó»ýÁ¸±â°£Àº 16.7°³¿ù
ÀÌ°í, 2³â ¹× 5³â »ýÁ¸À²Àº 20.1%, 4.1%·Î ³ªÅ¸³µ´Ù. »ýÁ¸À²¿¡ ´ëÇÑ ¿¹ÈÄ ÀÎÀÚ¸¦ ºÐ¼®ÇØ º¸
¾ÒÀ» ¶§, ´ÜÀϺ¯·®ºÐ¼®¿¡¼­ ÀÏÂ÷ ¼ö¼ú ÈÄ ±¹¼ÒÀç¹ß±îÁöÀÇ ±â°£ÀÌ À¯ÀÏÇÑ ¿¹ÈÄÀÎÀÚ·Î ³ªÅ¸³µ
´Ù. ±× ¿Ü ¿¬·É, ¼ºº°, ÀÓ»ó¼öÇà´É·ÂÁ¤µµ, Àç¹ßºÎÀ§, Ãʱ⺴±â, Ãʱ⠼ö¼ú¹æ¹ý, ¿ø°ÝÀüÀÌ¿©ºÎ,
¹æ»ç¼±Á¶»ç·® µîÀº À¯ÀÇÇÑ ÀÎÀÚ·Î °üÂûµÇÁö ¾Ê¾Ò´Ù. Áï ÀÏÂ÷ ¼ö¼ú ÈÄ ±¹¼ÒÀç¹ß±îÁöÀÇ ±â°£
ÀÌ 1³â ÀÌ»óÀÎ °æ¿ì¿¡¼­ 1³â ÀÌÇÏ¿¡ ºñÇØ ÀǹÌÀÖ°Ô ³ôÀº »ýÁ¸À²ÀÌ °üÂûµÇ¾ú´Ù(2³â ¹× 5³â
»ýÁ¸À²:42.0%, 8.4% vs 0.0%, 0.0%)(P<0.05). ´Ùº¯·®ºÐ¼®¿¡¼­µµ »ýÁ¸À²°ú ¿¬°üµÈ ¿¹ÈÄ ÀÎÀÚ
·Î´Â ÀÏÂ÷ ¼ö¼úÈÄ ±¹¼ÒÀç¹ß±îÁöÀÇ ±â°£¸¸ÀÌ ÀǹÌÀÖ°Ô °üÂûµÇ¾ú´Ù.
°á ·Ð : º» ¿¬±¸¿¡¼­´Â ¹æ»ç¼±Ä¡·á°¡ ±¹¼ÒÀç¹ßµÈ Á÷Àå¾ÏȯÀÚ¿¡¼­ º´º¯À¸·Î ÀÎÇÑ Áõ»óÀ»
¿ÏÈ­½ÃÅ°´Â µ¥ È¿°úÀûÀ̸ç, ÀϺÎÀÇ È¯ÀÚ¿¡¼­´Â Àå±â°£ÀÇ »ýÁ¸ÀÌ °¡´ÉÇÔÀ» ¾Ë ¼ö ÀÖ¾ú´Ù. ±×
·¯³ª, ÀüüÀûÀ¸·Î 2³â ¹× 5³â »ýÁ¸À²ÀÌ ÀúÁ¶ÇÏ°Ô ³ªÅ¸³µ°í, ÀÏÂ÷ ¼ö¼ú ÈÄ ±¹¼ÒÀç¹ß±îÁöÀÇ ±â
°£ÀÌ »ýÁ¸À²¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â °ÍÀ¸·Î °üÂûµÇ¾î, ÇâÈÄ ±¹¼Ò Àç¹ßµÈ Á÷Àå¾ÏȯÀÚ¿¡¼­ »ýÁ¸À²ÀÇ
Çâ»óÀ» À§ÇÑ È¿°úÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ ¿¬±¸°¡ ÇÊ¿äÇÏ°Ú°í, ´õºÒ¾î Ãʱâ Ä¡·á ÈÄ ±¹¼ÒÀç¹ß¹æ
Áö¸¦ À§ÇØ ºÎ°¡Ä¡·á¿¡ ´ëÇÑ Àû±ØÀûÀÎ ¿¬±¸°¡ ¿ì¼±µÇ¾î¾ß°Ú´Ù.

Purpose : We reviewed the treatment results for the patients with locally recurrent
rectal carcinoma. The object was to evaluate th6 treatment outcome and to identify the
prognostic factors influencing the survival.
Methods and Materials : Twenty-eight patients with locally recurrent rectal carcinoma
treated principally with external-beam radiation therapy between 1982 to 1996 in the
Department of Radiation Oncology at Paik and Hanyang Hospital were reviewed
retrospectively. Of these, 17 patients had initially abdominoperineal resection, 9 had low
anterior resection, and 2 had local excision. No patients had received adjuvant radiation
therapy for the primary disease. There were 14 men and 14 women whose ages ranged
from 31 to 72 years (median age:54.5). Median time from initial surgery to the start of
radiation therapy for local recurrence was 11 months (4¡­47 months). Radiation therapy
was given with total doses ranging from 27 to 64.8 §í (median=51.2 §í).
Results : The median survival was 16.7 months. The 2-year and 5-year survival rates
were 20.1%, 4.1% respectively. Upon multivariate analysis, overall survival was
positively correlated with duration of intervals from initial surgery to local recurrence
(P=0.039). Relief of pelvic symptoms was achieved in 17 of 28 patients (60.7%). Pain and
bleeding responded in 40% and 100% of patients, respectively.
Conclusion : Patients with locally recurrent rectal carcinoma treated with radiotherapy
have benefited symptomatically, and might have increased survivals with a small chance
of cure. But, patient were rarely cured (median survival:10 months, 5-year survival: less
than 5%). Overall survival was positively correlated with long intervals from initial
surgery to local recurrence. Future efforts should be directed to the use of effective
therapy for patients with locally recurrent rectal carcinoma and adjuvant therapy for
patients with rectal cancer to reduce the incidence of pelvic recurrence.

Å°¿öµå

±¹¼ÒÀç¹ß; Á÷Àå¾Ï; ¹æ»ç¼±Ä¡·á; Recurrence; Rectal carcinoma; Radiotherapy;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS